New insights into the pathophysiology of dyslipidemia in type 2 diabetes

Atherosclerosis

Volumn 239, Issue 2, 2015, Pages 483-495

  Taskinen, Marja Riitta ^a   Borén, Jan ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

CVD; De novo lipogenesis (DNL); Dyslipidemia; Fatty liver; Triglycerides; Type 2 diabetes; oxidation

Indexed keywords

APOLIPOPROTEIN C3; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; TRIGLYCERIDE RICH LIPOPROTEIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; CHOLESTEROL; GLUCOSE BLOOD LEVEL;

ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; DE NOVO LIPOGENESIS; DISEASE ASSOCIATION; DISORDERS OF LIPOPROTEIN METABOLISM; DYSLIPIDEMIA; FATTY ACID DESATURATION; FATTY ACID OXIDATION; GENETIC SUSCEPTIBILITY; HUMAN; INSULIN RESISTANCE; KINETICS; LIPID METABOLISM; LIPOGENESIS; LIPOPROTEIN SECRETION; LIPOPROTEIN SYNTHESIS; LIVER; LIVER CELL; LIVER FAT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; ANIMAL; BLOOD; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; DYSLIPIDEMIAS; GLUCOSE BLOOD LEVEL; INTESTINE; METABOLISM; RISK ASSESSMENT; RISK FACTOR;

ANIMALS; BIOMARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; HYPOLIPIDEMIC AGENTS; INTESTINES; LIPID METABOLISM; LIPOPROTEINS; LIVER; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; TRIGLYCERIDES;

EID: 84922981838     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.01.039     Document Type: Review

References (250)

1. Guariguata L., Whiting D.R., Hambleton I., et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res. Clin. Pract. 2014, 103:137-149.
2. Zimmet P.Z., Magliano D.J., Herman W.H., et al. Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol. 2014, 2:56-64.
3. Whiting D.R., Guariguata L., Weil C., et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res. Clin. Pract. 2011, 94:311-321.
4. Shaw J.E., Sicree R.A., Zimmet P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 2010, 87:4-14.
5. Joseph J.J., Golden S.H. Type 2 diabetes and cardiovascular disease: what next?. Curr. Opin. Endocrinol. Diabetes Obes. 2014, 21:109-120.
6. Emerging Risk Factors Collaboration, Seshasai S.R., Kaptoge S., Thompson A., et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011, 364:829-841.
7. Gregg E.W., Li Y., Wang J., et al. Changes in diabetes-related complications in the United States, 1990-2010. N.Engl. J. Med. 2014, 370:1514-1523.
8. Faerch K., Carstensen B., Almdal T.P., et al. Improved survival among patients with complicated type 2 diabetes in Denmark: a prospective study (2002-2010). J.Clin. Endocrinol. Metab. 2014, 99:E642-E646.
9. Emerging Risk Factors Collaboration, Sarwar N., Gao P., et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375:2215-2222.
10. Sattar N. Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia 2013, 56:686-695.
11. Vilbergsson S., Sigurdsson G., Sigvaldason H., et al. Coronary heart disease mortality amongst non-insulin-dependent diabetic subjects in Iceland: the independent effect of diabetes. The Reykjavik Study 17-year follow up. J.Intern. Med. 1998, 244:309-316.
12. Haffner S.M., Lehto S., Ronnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabettic subjects with and without prior myocardial infarction. N. Engl. J. Med. 1998, 339:229-234.
13. Boden W.E., Probstfield J.L., Anderson T., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N.Engl. J. Med. 2011, 365:2255-2267.
14. Group H.T.C., Landray M.J., Haynes R., et al. Effects of extended-release niacin with laropiprant in high-risk patients. N.Engl. J. Med. 2014, 371:203-212.
15. Taskinen M.R. Type 2 diabetes as a lipid disorder. Curr. Mol. Med. 2005, 5:297-308.
16. Chapman M.J., Ginsberg H.N., Amarenco P., et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart J. 2011, 32:1345-1361.
17. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683-689.
18. Scott R., Donoghoe M., Watts G.F., et al. Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. Cardiovasc. Diabetol. 2011, 10:102.
19. Eriksson M., Zethelius B., Eeg-Olofsson K., et al. Blood lipids in 75,048 type 2 diabetic patients: a population-based survey from the Swedish National Diabetes Register. Eur. J. Cardiovasc. Prev. Rehabil. Off. J. Eur. Soc. Cardiol. 2011, 18:97-105. Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
20. Feher M., Greener M., Munro N. Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus. Diabetes Metab. Syndr. Obes. 2013, 6:11-15.
21. Leiter L.A., Lundman P., da Silva P.M., et al. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet. Med. 2011, 28:1343-1351.
22. Reiner Z., De Bacquer D., Kotseva K., et al. Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey. Atherosclerosis 2013, 231:300-307.
23. Olofsson S.O., Boren J. Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J.Intern. Med. 2005, 258:395-410.
24. Wang X., Chauhan V., Nguyen A.T., et al. Immunochemical evidence that human apoB differs when expressed in rodent versus human cells. J.Lipid Res. 2003, 44:547-553.
25. Segrest J.P., Jones M.K., Mishra V.K., et al. Apolipoprotein B-100: conservation of lipid-associating amphipathic secondary structural motifs in nine species of vertebrates. J.Lipid Res. 1998, 39:85-102.
26. Hussain M.M. Intestinal lipid absorption and lipoprotein formation. Curr. Opin. Lipidol. 2014, 25:200-206.
27. Demignot S., Beilstein F., Morel E. Triglyceride-rich lipoproteins and cytosolic lipid droplets in enterocytes: key players in intestinal physiology and metabolic disorders. Biochimie 2014, 96:48-55.
28. Lambert J.E., Parks E.J. Postprandial metabolism of meal triglyceride in humans. Biochim. Biophys. Acta 2012, 1821:721-726.
29. Iqbal J., Hussain M.M. Evidence for multiple complementary pathways for efficient cholesterol absorption in mice. J.Lipid Res. 2005, 46:1491-1501.
30. Hiukka A., Fruchart-Najib J., Leinonen E., et al. Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes. Diabetologia 2005, 48:1207-1215.
31. Brunzell J.D., Hazzard W.R., Porte D., et al. Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J.Clin. Investig. 1973, 52:1578-1585.
32. Adiels M., Matikainen N., Westerbacka J., et al. Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity. Atherosclerosis 2012, 222:222-228.
33. Boren J., Taskinen M.R., Olofsson S.O., et al. Ectopic lipid storage and insulin resistance: a harmful relationship. J.Intern. Med. 2013, 274:25-40.
34. Olofsson S.O., Boren J. Apolipoprotein B secretory regulation by degradation. Arterioscler. Thromb. Vasc. Biol. 2012, 32:1334-1338.
35. Abumrad N.A., Davidson N.O. Role of the gut in lipid homeostasis. Physiol. Rev. 2012, 92:1061-1085.
36. Xiao C., Lewis G.F. Regulation of chylomicron production in humans. Biochim. Biophys. Acta 2012, 1821:736-746.
37. Veilleux A., Grenier E., Marceau P., et al. Intestinal lipid handling: evidence and implication of insulin signaling abnormalities in human obese subjects. Arterioscler. Thromb. Vasc. Biol. 2014, 34:644-653.
38. Xiao C., Dash S., Morgantini C., et al. New and emerging regulators of intestinal lipoprotein secretion. Atherosclerosis 2014, 233:608-615.
39. Cohn J.S., Johnson E.J., Millar J.S., et al. Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. J.Lipid Res. 1993, 34:2033-2040.
40. Karpe F., Bell M., Bjorkegren J., et al. Quantification of postprandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoproteins B-48 and B-100. Arterioscler. Thromb. Vasc. Biol. 1995, 15:199-207.
41. Xiao C., Bandsma R.H., Dash S., et al. Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans. Arterioscler. Thromb. Vasc. Biol. 2012, 32:1513-1519.
42. Dash S., Xiao C., Morgantini C., et al. Glucagon-like peptide-2 regulates release of chylomicrons from the intestine. Gastroenterology 2014, 147. 1275-1284.e1274.
43. Dash S., Xiao C., Morgantini C., et al. Glucagon-like peptide-2 acutely stimulates chylomicron release in healthy humans. Diabetes 2013, 62:A76-A77.
44. Xiao C., Dash S., Morgantini C., et al. Novel role of enteral monosaccharides in intestinal lipoprotein production in healthy humans. Arterioscler. Thromb. Vasc. Biol. 2013, 33:1056-1062.
45. Dash S., Xiao C., Morgantini C., et al. High-dose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men. Arterioscler. Thromb. Vasc. Biol. 2013, 33:2895-2901.
46. Tremblay A.J., Lamarche B., Hogue J.C., et al. Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. J.Lipid Res. 2009, 50:1463-1471.
47. Cani P.D., Possemiers S., Van de Wiele T., et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009, 58:1091-1103.
48. Adiels M., Taskinen M.R., Packard C., et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006, 49:755-765.
49. Verges B. Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes. Atherosclerosis 2010, 211:353-360.
50. Zammit V.A. Hepatic triacylglycerol synthesis and secretion: DGAT2 as the link between glycaemia and triglyceridaemia. Biochem. J. 2013, 451:1-12.
51. Perry R.J., Samuel V.T., Petersen K.F., et al. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 2014, 510:84-91.
52. Sun Z., Lazar M.A. Dissociating fatty liver and diabetes. Trends Endocrinol. Metab. 2013, 24:4-12.
53. Taskinen M.R., Adiels M., Westerbacka J., et al. Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects. Arterioscler. Thromb. Vasc. Biol. 2011, 31:2144-2150.
54. Boren J., Taskinen M.R., Adiels M. Kinetic studies to investigate lipoprotein metabolism. J.Intern Med. 2012, 271:166-173.
55. Adiels M., Westerbacka J., Soro-Paavonen A., et al. Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia 2007, 50:2356-2365.
56. Adiels M., Taskinen M.R., Boren J. Fatty liver, insulin resistance, and dyslipidemia. Curr. Diabetes Rep. 2008, 8:60-64.
57. Sparks J.D., Sparks C.E., Adeli K. Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. 2012, 32:2104-2112.
58. Fisher E., Lake E., McLeod R.S. Apolipoprotein B100 quality control and the regulation of hepatic very low density lipoprotein secretion. J.Biomed. Res. 2014, 28:178-193.
59. Haas M.E., Attie A.D., Biddinger S.B. The regulation of ApoB metabolism by insulin. Trends Endocrinol. Metab. 2013, 24:391-397.
60. Czech M.P., Tencerova M., Pedersen D.J., et al. Insulin signalling mechanisms for triacylglycerol storage. Diabetologia 2013, 56:949-964.
61. Otero Y.F., Stafford J.M., McGuinness O.P. Pathway-selective insulin resistance and metabolic disease: the importance of nutrient flux. J.Biol. Chem. 2014, 289:20462-20469.
62. Lewis G.F., Uffelman K.D., Szeto L.W., et al. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J.Clin. Investig. 1995, 95:158-166.
63. Timlin M.T., Barrows B.R., Parks E.J. Increased dietary substrate delivery alters hepatic fatty acid recycling in healthy men. Diabetes 2005, 54:2694-2701.
64. Nielsen S., Karpe F. Determinants of VLDL-triglycerides production. Curr. Opin. Lipidol. 2012, 23:321-326.
65. Tchernof A., Despres J.P. Pathophysiology of human visceral obesity: an update. Physiol. Rev. 2013, 93:359-404.
66. Zammit V.A. Role of insulin in hepatic fatty acid partitioning: emerging concepts. Biochem. J. 1996, 314(Pt 1):1-14.
67. Hodson L., Frayn K.N. Hepatic fatty acid partitioning. Curr. Opin. Lipidol. 2011, 22:216-224.
68. Havel R.J., Kane J.P., Balasse E.O., et al. Splanchnic metabolism of free fatty acids and production of triglycerides of very low density lipoproteins in normotriglyceridemic and hypertriglyceridemic humans. J.Clin. Investig. 1970, 49:2017-2035.
69. Nielsen S., Guo Z., Johnson C.M., et al. Splanchnic lipolysis in human obesity. J.Clin. Invest. 2004, 113:1582-1588.
70. Koutsari C., Jensen M.D. Thematic review series: patient-oriented research. Free fatty acid metabolism in human obesity. J.Lipid Res. 2006, 47:1643-1650.
71. Rui L. Energy metabolism in the liver. Compr. Physiol. 2014, 4:177-197.
72. Donnelly K.L., Smith C.I., Schwarzenberg S.J., et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J.Clin. Invest. 2005, 115:1343-1351.
73. Koppe S.W. Obesity and the liver: nonalcoholic fatty liver disease. Transl. Res. 2014, 164:312-322.
74. Rinella M.E., Sanyal A.J. NAFLD in 2014: genetics, diagnostics and therapeutic advances in NAFLD. Nat. Rev. Gastroenterol. Hepatol. 2015, 2:65-66.
75. Anstee Q.M., Day C.P. The genetics of NAFLD. Nat. Rev. Gastroenterol. Hepatol. 2013, 10:645-655.
76. Romeo S., Kozlitina J., Xing C., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2008, 40:1461-1465.
77. Speliotes E.K., Yerges-Armstrong L.M., Wu J., et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011, 7:e1001324.
78. Victor R.G., Haley R.W., Willett D.L., et al. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am. J. Cardiol. 2004, 93:1473-1480.
79. Kozlitina J., Smagris E., Stender S., et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2014, 46:352-356.
80. Kumari M., Schoiswohl G., Chitraju C., et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell. Metab. 2012, 15:691-702.
81. Basantani M.K., Sitnick M.T., Cai L., et al. Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. J.Lipid Res. 2011, 52:318-329.
82. Smagris E., BasuRay S., Li J., et al. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology 2015, 61:108-118.
83. Pirazzi C., Adiels M., Burza M.A., et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and invitro. J.Hepatol. 2012, 57:1276-1282.
84. Petersen K.F., Dufour S., Hariri A., et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N.Engl. J. Med. 2010, 362:1082-1089.
85. Kozlitina J., Boerwinkle E., Cohen J.C., et al. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology 2011, 53:467-474.
86. Valenti L., Nobili V., Al-Serri A., et al. The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. J.Hepatol. 2011, 55:1409-1414.
87. Sentinelli F., Romeo S., Maglio C., et al. Lack of effect of apolipoprotein C3 polymorphisms on indices of liver steatosis, lipid profile and insulin resistance in obese Southern Europeans. Lipids Health Dis. 2011, 10:93.
88. Peter A., Kantartzis K., Machicao F., et al. Visceral obesity modulates the impact of apolipoprotein C3 gene variants on liver fat content. Int. J. Obes. Lond 2012, 36:774-782.
89. Vedala A., Wang W., Neese R.A., et al. Delayed secretory pathway contributions to VLDL-triglycerides from plasma NEFA, diet, and de novo lipogenesis in humans. J.Lipid Res. 2006, 47:2562-2574.
90. Diraison F., Moulin P., Beylot M. Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab. 2003, 29:478-485.
91. Schwarz J.M., Linfoot P., Dare D., et al. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am. J. Clin. Nutr. 2003, 77:43-50.
92. Wilke M.S., French M.A., Goh Y.K., et al. Synthesis of specific fatty acids contributes to VLDL-triacylglycerol composition in humans with and without type 2 diabetes. Diabetologia 2009, 52:1628-1637.
93. Marques-Lopes I., Ansorena D., Astiasaran I., et al. Postprandial de novo lipogenesis and metabolic changes induced by a high-carbohydrate, low-fat meal in lean and overweight men. Am. J. Clin. Nutr. 2001, 73:253-261.
94. Birkenfeld A.L., Shulman G.I. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 2014, 59:713-723.
95. Berlanga A., Guiu-Jurado E., Porras J.A., et al. Molecular pathways in non-alcoholic fatty liver disease. Clin. Exp. Gastroenterol. 2014, 7:221-239.
96. Xu X., So J.S., Park J.G., et al. Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP. Semin. Liver Dis. 2013, 33:301-311.
97. Karagianni P., Talianidis I. Transcription factor networks regulating hepatic fatty acid metabolism. Biochim. Biophys. Acta 2015, 1851:2-8.
98. Ferre P., Foufelle F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes. Metab. 2010, 12(Suppl.2):83-92.
99. Lodhi I.J., Wei X., Semenkovich C.F. Lipoexpediency: de novo lipogenesis as a metabolic signal transmitter. Trends Endocrinol. Metab. 2011, 22:1-8.
100. Postic C., Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J.Clin. Investig. 2008, 118:829-838.
101. Jensen-Urstad A.P., Semenkovich C.F. Fatty acid synthase and liver triglyceride metabolism: housekeeper or messenger?. Biochim. Biophys. Acta 2012, 1821:747-753.
102. Yee J.K., Mao C.S., Hummel H.S., et al. Compartmentalization of stearoyl-coenzyme A desaturase 1 activity in HepG2 cells. J.Lipid Res. 2008, 49:2124-2134.
103. Gong J., Campos H., McGarvey S., et al. Adipose tissue palmitoleic acid and obesity in humans: does it behave as a lipokine?. Am. J. Clin. Nutr. 2011, 93:186-191.
104. Hodson L., Fielding B.A. Stearoyl-CoA desaturase: rogue or innocent bystander?. Prog. Lipid Res. 2013, 52:15-42.
105. Lee J.J., Lambert J.E., Hovhannisyan Y., et al. Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis. Am. J. Clin. Nutr. 2015, 101:34-43.
106. Aarsland A., Wolfe R.R. Hepatic secretion of VLDL fatty acids during stimulated lipogenesis in men. J.Lipid Res. 1998, 39:1280-1286.
107. Field C.J., Ryan E.A., Thomson A.B., et al. Diet fat composition alters membrane phospholipid composition, insulin binding, and glucose metabolism in adipocytes from control and diabetic animals. J.Biol. Chem. 1990, 265:11143-11150.
108. Cao H., Gerhold K., Mayers J.R., et al. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell 2008, 134:933-944.
109. Sampath H., Ntambi J.M. The role of stearoyl-CoA desaturase in obesity, insulin resistance, and inflammation. Ann. N. Y. Acad. Sci. 2011, 1243:47-53.
110. Kroger J., Schulze M.B. Recent insights into the relation of Delta5 desaturase and Delta6 desaturase activity to the development of type 2 diabetes. Curr. Opin. Lipidol. 2012, 23:4-10.
111. Kotronen A., Seppanen-Laakso T., Westerbacka J., et al. Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes 2009, 58:203-208.
112. Stefan N., Peter A., Cegan A., et al. Low hepatic stearoyl-CoA desaturase 1 activity is associated with fatty liver and insulin resistance in obese humans. Diabetologia 2008, 51:648-656.
113. Silbernagel G., Kovarova M., Cegan A., et al. High hepatic SCD1 activity is associated with low liver fat content in healthy subjects under a lipogenic diet. J.Clin. Endocrinol. Metab. 2012, 97:E2288-E2292.
114. Lambert J.E., Ramos-Roman M.A., Browning J.D., et al. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 2014, 146:726-735.
115. Matikainen N., Adiels M., Soderlund S., et al. Hepatic lipogenesis and a marker of hepatic lipid oxidation, predict postprandial responses of triglyceride-rich lipoproteins. Obesity Silver Spring 2014, 22:1854-1859.
116. Ameer F., Scandiuzzi L., Hasnain S., et al. De novo lipogenesis in health and disease. Metabolism 2014, 63:895-902.
117. Mashek D.G. Hepatic fatty acid trafficking: multiple forks in the road. Adv. Nutr. 2013, 4:697-710.
118. Lopez-Miranda J., Vilella E., Perez-Jimenez F., et al. Low-density lipoprotein metabolism in rats treated with cyclosporine. Metabolism 1993, 42:678-683.
119. Stefan N., Haring H.U. The metabolically benign and malignant fatty liver. Diabetes 2011, 60:2011-2017.
120. Gruben N., Shiri-Sverdlov R., Koonen D.P., et al. Nonalcoholic fatty liver disease: a main driver of insulin resistance or a dangerous liaison?. Biochim. Biophys. Acta 2014, 1842:2329-2343.
121. Jin Y., McFie P.J., Banman S.L., et al. Diacylglycerol acyltransferase-2 (DGAT2) and monoacylglycerol acyltransferase-2 (MGAT2) interact to promote triacylglycerol synthesis. J.Biol. Chem. 2014, 289:28237-28248.
122. Pagadala M., Kasumov T., McCullough A.J., et al. Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol. Metab. 2012, 23:365-371.
123. Magkos F., Su X., Bradley D., et al. Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. Gastroenterology 2012, 142. 1444-1446.e1442.
124. Innerarity T.L., Boren J., Yamanaka S., et al. Biosynthesis of apolipoprotein B48-containing lipoproteins. Regulation by novel post-transcriptional mechanisms. J.Biol. Chem. 1996, 271:2353-2356.
125. Adiels M., Olofsson S.O., Taskinen M.R., et al. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1225-1236.
126. Boren J., Graham L., Wettesten M., et al. The assembly and secretion of ApoB 100-containing lipoproteins in Hep G2 cells. ApoB 100 is cotranslationally integrated into lipoproteins. J.Biol. Chem. 1992, 267:9858-9867.
127. Wetterau J.R., Zilversmit D.B. Purification and characterization of microsomal triglyceride and cholesteryl ester transfer protein from bovine liver microsomes. Chem. Phys. Lipids 1985, 38:205-222.
128. Rutledge A.C., Su Q., Adeli K. Apolipoprotein B100 biogenesis: a complex array of intracellular mechanisms regulating folding, stability, and lipoprotein assembly. Biochem. Cell. Biol. 2010, 88:251-267.
129. Olofsson S.O., Wiklund O., Boren J. Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. Vasc. Health Risk Manag. 2007, 3:491-502.
130. Stillemark-Billton P., Beck C., Boren J., et al. Relation of the size and intracellular sorting of apoB to the formation of VLDL 1 and VLDL 2. J.Lipid Res. 2005, 46:104-114.
131. Yao Z., Zhou H., Figeys D., et al. Microsome-associated lumenal lipid droplets in the regulation of lipoprotein secretion. Curr. Opin. Lipidol. 2013, 24:160-170.
132. Ramasamy I. Recent advances in physiological lipoprotein metabolism. Clin. Chem. Lab. Med. 2014, 52:1695-1727.
133. Bostrom K., Wettesten M., Boren J., et al. Pulse-chase studies of the synthesis and intracellular transport of apolipoprotein B-100 in Hep G2 cells. J.Biol. Chem. 1986, 261:13800-13806.
134. Olofsson S.O., Boren J. Apolipoprotein B secretory regulation by degradation. Arterioscler. Thromb. Vasc. Biol. 2012, 32:1334-1338.
135. Fisher E.A., Ginsberg H.N. Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J.Biol. Chem. 2002, 277:17377-17380.
136. Fisher E.A., Pan M., Chen X., et al. The triple threat to nascent apolipoprotein B. Evidence for multiple, distinct degradative pathways. J.Biol. Chem. 2001, 276:27855-27863.
137. Pan M., Cederbaum A.I., Zhang Y.L., et al. Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J.Clin. Investig. 2004, 113:1277-1287.
138. Brodsky J.L., Fisher E.A. The many intersecting pathways underlying apolipoprotein B secretion and degradation. Trends Endocrinol. Metab. 2008, 19:254-259.
139. Fisher E.A., Williams K.J. Autophagy of an oxidized, aggregated protein beyond the ER: a pathway for remarkably late-stage quality control. Autophagy 2008, 4:721-723.
140. Joven J., Vilella E., Ahmad S., et al. Lipoprotein heterogeneity in end-stage renal disease. Kidney Int. 1993, 43:410-418.
141. Wiggins D., Gibbons G.F. The lipolysis/esterification cycle of hepatic triacylglycerol. Its role in the secretion of very-low-density lipoprotein and its response to hormones and sulphonylureas. Biochem. J. 1992, 284:457-462.
142. Salter A.M., Wiggins D., Sessions V.A., et al. The intracellular triacylglycerol/fatty acid cycle: a comparison of its activity in hepatocytes which secrete exclusively apolipoprotein (apo) B100 very-low-density lipoprotein (VLDL) and in those which secrete predominantly apoB48 VLDL. Biochem. J. 1998, 332(Pt 3):667-672.
143. Gibbons G.F., Islam K., Pease R.J. Mobilisation of triacylglycerol stores. Biochim. Biophys. Acta 2000, 1483:37-57.
144. Sundaram M., Yao Z. Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion. Nutr. Metab. Lond. 2010, 7:35.
145. Olofsson S.-O., Bjursell G., Boström K., et al. Apolipoprotein B: structure, biosynthesis and role in the lipoprotein assembly process. Atherosclerosis 1987, 68:1-17.
146. Murphy D.J., Vance J. Mechanisms of lipid-body formation. Trends Biochem. Sci. 1999, 24:109-115.
147. Brown D.A. Lipid droplets: proteins floating on a pool of fat. Curr. Biol. 2001, 11:R446-R449.
148. Wang Y., Tran K., Yao Z. The activity of microsomal triglyceride transfer protein is essential for accumulation of triglyceride within microsomes in McA-RH7777 cells. A unified model for the assembly of very low density lipoproteins. J.Biol. Chem. 1999, 274:27793-27800.
149. Yao Z. Human apolipoprotein C-III - a new intrahepatic protein factor promoting assembly and secretion of very low density lipoproteins. Cardiovasc. Hematol. Disord. Drug Targets 2012, 12:133-140.
150. Yao Z., Wang Y. Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production. Curr. Opin. Lipidol. 2012, 23:206-212.
151. Sundaram M., Zhong S., Khalil M.B., et al. Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. J.Lipid Res. 2010, 51:150-161.
152. Qin W., Sundaram M., Wang Y., et al. Missense mutation in APOC3 within the C-terminal lipid binding domain of human ApoC-III results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins: evidence that ApoC-III plays a major role in the formation of lipid precursors within the microsomal lumen. J.Biol. Chem. 2011, 286:27769-27780.
153. Sundaram M., Zhong S., Khalil M.B., et al. Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia. J.Lipid Res. 2010, 51:1524-1534.
154. Musso G., Gambino R., Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog. Lipid Res. 2009, 48:1-26.
155. Ratziu V., Bellentani S., Cortez-Pinto H., et al. Aposition statement on NAFLD/NASH based on the EASL 2009 special conference. J.Hepatol. 2010, 53:372-384.
156. Kissebah A.H., Alfarsi S., Evans D.J., et al. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus. Diabetes 1982, 31:217-225.
157. Duvillard L., Pont F., Florentin E., et al. Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study. Eur. J. Clin. Investig. 2000, 30:685-694.
158. Ouguerram K., Magot T., Zair Y., et al. Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes. J.Pharmacol. Exp. Ther. 2003, 306:332-337.
159. Cummings M.H., Watts G.F., Umpleby A.M., et al. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetologia 1995, 38:959-967.
160. Wu X., Williams K.J. NOX4 pathway as a source of selective insulin resistance and responsiveness. Arterioscler. Thromb. Vasc. Biol. 2012, 32:1236-1245.
161. Aravinthan A., Challis B., Shannon N., et al. Selective insulin resistance in hepatocyte senescence. Exp. Cell Res. 2015, 331:38-45.
162. Kamagate A., Dong H.H. FoxO1 integrates insulin signaling to VLDL production. Cell. Cycle 2008, 7:3162-3170.
163. Wan M., Leavens K.F., Saleh D., et al. Postprandial hepatic lipid metabolism requires signaling through Akt2 independent of the transcription factors FoxA2, FoxO1, and SREBP1c. Cell. Metab. 2011, 14:516-527.
164. Leavens K.F., Birnbaum M.J. Insulin signaling to hepatic lipid metabolism in health and disease. Crit. Rev. Biochem. Mol. Biol. 2011, 46:200-215.
165. Kamagate A., Qu S., Perdomo G., et al. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J.Clin. Investig. 2008, 118:2347-2364.
166. Ai D., Baez J.M., Jiang H., et al. Activation of ER stress and mTORC1 suppresses hepatic sortilin-1 levels in obese mice. J.Clin. Investig. 2012, 122:1677-1687.
167. Strong A., Ding Q., Edmondson A.C., et al. Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. J.Clin. Investig. 2012, 122:2807-2816.
168. Andersson L., Bostrom P., Ericson J., et al. PLD1 and ERK2 regulate cytosolic lipid droplet formation. J.Cell. Sci. 2006, 119:2246-2257.
169. Adiels M., Boren J., Caslake M.J., et al. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1697-1703.
170. Taskinen M.R. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003, 46:733-749.
171. Malmstrom R., Packard C.J., Watson T.D., et al. Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler. Thromb. Vasc. Biol. 1997, 17:1454-1464.
172. Lewis G.F., Uffelman K.D., Szeto L.W., et al. Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes 1993, 42:833-842.
173. Cummings M.H., Watts G.F., Umpleby A.M., et al. Acute hyperinsulinemia decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetes 1995, 44:1059-1065.
174. Sondergaard E., Sorensen L.P., Rahbek I., et al. Postprandial VLDL-triacylglycerol secretion is not suppressed in obese type 2 diabetic men. Diabetologia 2012, 55:2733-2740.
175. Fabbrini E., Magkos F., Mohammed B.S., et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:15430-15435.
176. Sorensen L.P., Sondergaard E., Nellemann B., et al. Increased VLDL-triglyceride secretion precedes impaired control of endogenous glucose production in obese, normoglycemic men. Diabetes 2011, 60:2257-2264.
177. Sahini N., Borlak J. Recent insights into the molecular pathophysiology of lipid droplet formation in hepatocytes. Prog. Lipid Res. 2014, 54:86-112.
178. Begriche K., Massart J., Robin M.A., et al. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology 2013, 58:1497-1507.
179. Ruderman N.B., Dean D. Malonyl CoA, long chain fatty acyl CoA and insulin resistance in skeletal muscle. J.Basic Clin. Physiol. Pharmacol. 1998, 9:295-308.
180. Veech R.L. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism,. Prostagl. Leukot. Essent. Fat. Acids 2004, 70:309-319.
181. Nakamura M.T., Yudell B.E., Loor J.J. Regulation of energy metabolism by long-chain fatty acids. Prog. Lipid Res. 2014, 53:124-144.
182. Bechmann L.P., Hannivoort R.A., Gerken G., et al. The interaction of hepatic lipid and glucose metabolism in liver diseases. J.Hepatol. 2012, 56:952-964.
183. Fu S., Watkins S.M., Hotamisligil G.S. The role of endoplasmic reticulum in hepatic lipid homeostasis and stress signaling,. Cell. Metab. 2012, 15:623-634.
184. Mandard S., Muller M., Kersten S. Peroxisome proliferator-activated receptor alpha target genes. Cell. Mol. Life Sci. 2004, 61:393-416.
185. Rakhshandehroo M., Knoch B., Muller M., et al. Peroxisome proliferator-activated receptor alpha target genes. PPAR Res. 2010, 2010.
186. Crunkhorn S. Metabolic disorders: FGF21 analogue shows promise in the clinic. Nat. Rev. Drug Discov. 2013, 12:825.
187. Straczkowski M., Karczewska-Kupczewska M., Adamska A., et al. Serum fibroblast growth factor 21 in human obesity: regulation by insulin infusion and relationship with glucose and lipid oxidation. Int. J. Obes. 2013, 37:1386-1390.
188. Chow W.S., Xu A., Woo Y.C., et al. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. Arterioscler. Thromb. Vasc. Biol. 2013, 33:2454-2459.
189. Gaich G., Chien J.Y., Fu H., et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell. Metab. 2013, 18:333-340.
190. Li Y., Wong K., Giles A., et al. Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21. Gastroenterology 2014, 146. 539-549 e537.
191. Coskun T., Bina H.A., Schneider M.A., et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008, 149:6018-6027.
192. Zhang Y., Lei T., Huang J.F., et al. The link between fibroblast growth factor 21 and sterol regulatory element binding protein 1c during lipogenesis in hepatocytes. Mol. Cell. Endocrinol. 2011, 342:41-47.
193. Gaemers I.C., Stallen J.M., Kunne C., et al. Lipotoxicity and steatohepatitis in an overfed mouse model for non-alcoholic fatty liver disease. Biochim. Biophys. Acta 2011, 1812:447-458.
194. Dallinga-Thie G.M., Franssen R., Mooij H.L., et al. The metabolism of triglyceride-rich lipoproteins revisited: new players, new insight. Atherosclerosis 2010, 211:1-8.
195. Willecke F., Scerbo D., Nagareddy P., et al. Lipolysis, and not hepatic lipogenesis, is the primary modulator of triglyceride levels in streptozotocin-induced diabetic mice. Arterioscler. Thromb. Vasc. Biol. 2015, 35:102-110.
196. Kersten S. Physiological regulation of lipoprotein lipase. Biochim. Biophys. Acta 2014, 1841:919-933.
197. Marcoux C., Tremblay M., Fredenrich A., et al. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins. Metabolism 2001, 50:112-119.
198. Campos H., Perlov D., Khoo C., et al. Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia. J.Lipid Res. 2001, 42:1239-1249.
199. Hiukka A., Stahlman M., Pettersson C., et al. ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan. Diabetes 2009, 58:2018-2026.
200. Proctor S.D., Vine D.F., Mamo J.C. Arterial retention of apolipoprotein B(48)- and B(100)-containing lipoproteins in atherogenesis. Curr. Opin. Lipidol. 2002, 13:461-470.
201. Varbo A., Benn M., Davey Smith G., et al. Remnant cholesterol, low-density lipoprotein cholesterol, and blood pressure as mediators from obesity to ischemic heart disease. Circ. Res. 2014 Nov 19, pii: CIRCRESAHA.114.304846. [Epub ahead of print].
202. Nordestgaard B.G., Varbo A. Triglycerides and cardiovascular disease. Lancet 2014, 384:626-635.
203. Nakajima K., Saito T., Tamura A., et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin. Chim. Acta 1993, 223:53-71.
204. Fujioka Y., Ishikawa Y. Remnant lipoproteins as strong key particles to atherogenesis. J.Atheroscler. Thromb. 2009, 16:145-154.
205. McNamara J.R., Shah P.K., Nakajima K., et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis 2001, 154:229-236.
206. Kugiyama K., Doi H., Takazoe K., et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 1999, 99:2858-2860.
207. Varbo A., Benn M., Tybjaerg-Hansen A., et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J.Am. Coll. Cardiol. 2013, 61:427-436.
208. Jorgensen A.B., Frikke-Schmidt R., West A.S., et al. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur. Heart J. 2013, 34:1826-1833.
209. Varbo A., Benn M., Tybjaerg-Hansen A., et al. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation 2013, 128:1298-1309.
210. Thomsen M., Varbo A., Tybjaerg-Hansen A., et al. Low nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study. Clin. Chem. 2014, 60:737-746.
211. Triglyceride Coronary Disease Genetics Collaboration, Emerging Risk Factors Collaboration, Sarwar N., et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010, 375:1634-1639.
212. Teslovich T.M., Musunuru K., Smith A.V., et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010, 466:707-713.
213. Do R., Willer C.J., Schmidt E.M., et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat. Genet. 2013, 45:1345-1352.
214. Nordestgaard B.G., Langsted A., Freiberg J.J. Nonfasting hyperlipidemia and cardiovascular disease. Curr. Drug Targets 2009, 10:328-335.
215. Moreton J.R. Atherosclerosis and alimentary hyperlipemia. Science 1947, 106:190-191.
216. Moreton J.R. Physical state of lipids and foreign substances producing atherosclerosis. Science 1948, 107:371-373.
217. Chan D.C., Watts G.F., Redgrave T.G., et al. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metabolism 2002, 51:1041-1046.
218. Watts G.F., Barrett P.H., Ji J., et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 2003, 52:803-811.
219. Mero N., Malmstrom R., Steiner G., et al. Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease. Atherosclerosis 2000, 150:167-177.
220. Hassing H.C., Surendran R.P., Mooij H.L., et al. Pathophysiology of hypertriglyceridemia. Biochim. Biophys. Acta 2012, 1821:826-832.
221. Taskinen M.R. Lipoprotein lipase in diabetes. Diabetes Metab. Rev. 1987, 3:551-570.
222. Williams K.J., Chen K. Recent insights into factors affecting remnant lipoprotein uptake. Curr. Opin. Lipidol. 2010, 21:218-228.
223. Chen K., Liu M.L., Schaffer L., et al. Type 2 diabetes in mice induces hepatic overexpression of sulfatase 2, a novel factor that suppresses uptake of remnant lipoproteins. Hepatology 2010, 52:1957-1967.
224. Hassing H.C., Mooij H., Guo S., et al. Inhibition of hepatic sulfatase-2 invivo: a novel strategy to correct diabetic dyslipidemia. Hepatology 2012, 55:1746-1753.
225. Matikainen N., Burza M.A., Romeo S., et al. Genetic variation in SULF2 is associated with postprandial clearance of triglyceride-rich remnant particles and triglyceride levels in healthy subjects. PLoS One 2013, 8:e79473.
226. Hassing H.C., Surendran R.P., Derudas B., et al. SULF2 strongly prediposes to fasting and postprandial triglycerides in patients with obesity and type 2 diabetes mellitus. Obesity (Silver Spring) 2014, 22:1309-1316.
227. Wong A.T., Chan D.C., Pang J., et al. Plasma apolipoprotein B-48 transport in obese men: a new tracer kinetic study in the postprandial state. J.Clin. Endocrinol. Metab. 2014, 99:E122-E126.
228. Wong A.T., Chan D.C., Barrett P.H., et al. Effect of omega-3 fatty acid ethyl esters on apolipoprotein B-48 kinetics in obese subjects on a weight-loss diet: a new tracer kinetic study in the postprandial state. J.Clin. Endocrinol. Metab. 2014, 99:E1427-E1435.
229. Sun F., Stolinski M., Shojaee-Moradie F., et al. Anovel method for measuring intestinal and hepatic triacylglycerol kinetics. Am. J. Physiol. Endocrinol. Metab. 2013, 305:E1041-E1047.
230. Riches F.M., Watts G.F., Naoumova R.P., et al. Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity. Int. J. Obes. Relat. Metab. Disord. 1998, 22:414-423.
231. Pont F., Duvillard L., Florentin E., et al. Early kinetic abnormalities of apoB-containing lipoproteins in insulin-resistant women with abdominal obesity. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1726-1732.
232. Kissebah A.H., Alfarsi S., Evans D.J., et al. Plasma low density lipoprotein transport kinetics in noninsulin-dependent diabetes mellitus. J.Clin. Investig. 1983, 71:655-667.
233. Verges B. New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab. 2005, 31:429-439.
234. Stahlman M., Pham H.T., Adiels M., et al. Clinical dyslipidaemia is associated with changes in the lipid composition and inflammatory properties of apolipoprotein-B-containing lipoproteins from women with type 2 diabetes. Diabetologia 2012, 55:1156-1166.
235. Packard C.J. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem. Soc. Trans. 2003, 31:1066-1069.
236. Georgieva A.M., van Greevenbroek M.M., Krauss R.M., et al. Subclasses of low-density lipoprotein and very low-density lipoprotein in familial combined hyperlipidemia: relationship to multiple lipoprotein phenotype. Arterioscler. Thromb. Vasc. Biol. 2004, 24:744-749.
237. Feingold K.R., Grunfeld C., Pang M., et al. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler. Thromb. 1992, 12:1496-1502.
238. Baynes C., Henderson A.D., Anyaoku V., et al. The role of insulin insensitivity and hepatic lipase in the dyslipidaemia of type 2 diabetes,. Diabet. Med. 1991, 8:560-566.
239. Nikkila E.A., Huttunen J.K., Ehnholm C. Postheparin plasma lipoprotein lipase and hepatic lipase in diabetes mellitus. Relationship to plasma triglyceride metabolism. Diabetes 1977, 26:11-21.
240. Austin M.A., King M.-C., Vranizan K.M., et al. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990, 82:495-506.
241. Lamarche B., Tchernof A., Moorjani S., et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997, 95:69-75.
242. Gardner C.D., Fortmann S.P., Krauss R.M. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. J.Am. Med. Assoc. 1996, 276:875-881.
243. Vakkilainen J., Steiner G., Ansquer J.C., et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003, 107:1733-1737.
244. Sacks F.M., Campos H. Clinical review 163: cardiovascular endocrinology: low-density lipoprotein size and cardiovascular disease: a reappraisal. J.Clin. Endocrinol. Metab. 2003, 88:4525-4532.
245. Lada A.T., Rudel L.L. Associations of low density lipoprotein particle composition with atherogenicity. Curr. Opin. Lipidol. 2004, 15:19-24.
246. Rashid S., Watanabe T., Sakaue T., et al. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin. Biochem. 2003, 36:421-429.
247. Stahlman M., Fagerberg B., Adiels M., et al. Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort: Impact on small HDL particles. Biochim. Biophys. Acta 2013, 1831:1609-1617.
248. Borén J., Taskinen M.R., Olofsson S.O., Levin M. Ectopic lipid storage and insulin resistance: a harmful relationship. J Intern Med. 2013 Jul, 274(1):25-40.
249. Adiels M., Olofsson S.O., Taskinen M.R., et al. Diabetic dyslipidaemia. Curr. Opin. Lipidol. 2006, 17:238-246.
250. Watts G.F., Ooi E.M., Chan D.C. Demystifying the management of hypertriglyceridaemia. Nat. Rev. Cardiol. 2013, 10:648-661.